Elon Musk to testify in a case that could change the path of AI

A jury trial began over Elon Musk’s lawsuit against OpenAI, with Musk seeking a return to nonprofit status, the removal of Sam Altman and Greg Brockman, and about $130 billion in damages. The case centers on OpenAI’s shift from nonprofit to for-profit structures and could affect the company’s planned IPO as early as this year. OpenAI argues Musk’s claims are driven by jealousy and regret, while Microsoft is accused of aiding the alleged breach of charitable trust.

Analysis

This is less a binary legal event than a timing risk around OpenAI’s capital-formation path. The near-term market issue is not damages; it is whether the trial injects governance uncertainty into an IPO process that depends on clean narrative, board stability, and underwriter confidence. Even if Musk does not win broad remedies, discovery and public testimony can still create a multi-month overhang that widens the valuation discount versus private AI peers and raises the cost of capital for the entire AI ecosystem.

The second-order winner is xAI, but only if the case materially slows OpenAI’s fundraising or listing window. A delayed OpenAI IPO would likely force more capital to chase fewer scaled frontier-model assets, which can improve pricing for private AI infrastructure, model tooling, and power/compute providers. Microsoft is the cleanest public-market hedge: it remains the economic backstop to OpenAI exposure, but it also faces modest legal noise and potential contract renegotiation risk if the structure changes, so the stock’s reaction should be muted unless investors start pricing a real impairment to Azure AI attach rates.

The consensus may be overestimating the odds of a dramatic court-driven unwind and underestimating the duration of reputational damage. The likely base case is not structural reversal; it is a prolonged disclosure process that keeps OpenAI in the headlines during the exact period it needs a frictionless IPO story. That argues for a slower, grinding pressure trade rather than an immediate crash-and-rebound setup.

Catalyst timing matters: verdict/advisory findings could hit in days to weeks, while any governance remedy, appeal, or restructuring would play out over 6-18 months. The key reversal signal is any public indication that OpenAI’s financing or IPO timetable is unaffected; absent that, the trade should be expressed as event-driven volatility rather than outright directional collapse.

Key Decisions for Investors

• Buy MSFT on weakness only if the market overreacts to trial headlines; use a 3-6 month horizon and size for low beta, because the direct earnings hit is likely limited unless Azure/OpenAI economics are impaired.
• Short a basket of private AI enablers via public proxies on any OpenAI-IPO delay narrative: consider a pair of long MSFT vs short high-multiple AI infrastructure names for 1-3 months, aiming to capture a valuation reset if capital formation gets pushed out.
• Use options to express event risk: buy near-dated straddles on MSFT only if implied volatility is not already elevated; otherwise, sell upside calls against existing longs to monetize headline-driven premium decay over the next 2-4 weeks.
• If the trial meaningfully slows OpenAI’s fundraising, rotate toward xAI-adjacent winners through broader AI compute/power beneficiaries rather than direct exposure to the litigation; the trade works best as a relative-value basket over 6-12 months.
• Avoid chasing an outright short in MSFT solely on the lawsuit; risk/reward is poor unless there is evidence of contract disruption or IPO cancellation, which is a lower-probability tail event.